External Source

Study Of Real-world Evidence In Patients With Pms And Rms Treated With Ocrelizumab

2022 3:33
Synopsis
Ocrelizumab is an anti-CD20 antibody used to treat relapsing (RMS) and progressive multiple sclerosis (PMS). Virginia ...

You Might Also Like

Daniel Ontaneda, MD: Real-World Observations With Ocrelizumab 5:11
Daniel Ontaneda, Md: Real-world Observations With Ocrelizuma...
2019
Long-term results of ocrelizumab in treatment-naive patients with early relapsing MS 4:32
Long-term Results Of Ocrelizumab In Treatment-naive Patients...
2022
Safely switching from natalizumab to ocrelizumab in patients with MS at risk of PML 2:14
Safely Switching From Natalizumab To Ocrelizumab In Patients...
2021
Using Real World Evidence to Weight Efficacy of Treatment 4:14
Using Real World Evidence To Weight Efficacy Of Treatment
2016
ACAPELLA: Real-World Experience with Ocrelizumab, Year Three Data 3:00
Acapella: Real-world Experience With Ocrelizumab, Year Three...
2022
Impact of ocrelizumab disruption on RRMS 2:52
Impact Of Ocrelizumab Disruption On Rrms
2022
No Evidence of Disease Activity With Ocrelizumab for Multiple Sclerosis 2:27
No Evidence Of Disease Activity With Ocrelizumab For Multipl...
2016
Real-World Evidence as a Mechanism for Patient-Centric Care 2:57
Real-world Evidence As A Mechanism For Patient-centric Care
2017
ENSEMBLE Study Results, Ocrelizumab as Promising Early Treatment for MS 5:54
Ensemble Study Results, Ocrelizumab As Promising Early Treat...
2023
Ocrelizumab in Primary Progressive Multiple Sclerosis (PPMS) 20:37
Ocrelizumab In Primary Progressive Multiple Sclerosis (ppms)
2017
Consistent Real World Efficacy of Ofatumumab Therapy for Multiple Sclerosis 2:41
Consistent Real World Efficacy Of Ofatumumab Therapy For Mul...
2024
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.